Company: CERO
Filing Date: 2025-10-30
Form Type: 424B3
Source: 0001213900-25-104118
Chunk: 2

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-10-30
Form: 424B3
Chunk 2
---
� | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)                 |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                                                                         |     | Trading Symbol(s) |     | Name of each exchange on which registered |
| Common stock, par value $0.0001 per share                                                   |     | CERO              |     | NASDAQ Capital Market                     |
| Warrants, each whole warrant exercisable for one two-thousandths of a share of common stock |     | CEROW             |     | NASDAQ Capital Market                     |

Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed,
on August 28, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), received a letter
from the staff at the Nasdaq Listing Qualifications department notifying the Company that such staff had determined that the Company does
not comply with the minimum stockholders’ equity requirement of $2,500,000 (the “Stockholders’ Equity Requirement”)
for continued listing on the Nasdaq Capital Market (“Nasdaq”) set forth in Nasdaq Rule 5550(b).

As also previously disclosed,
on September 3, 2025, the Company requested a hearing to appeal such determination before a panel (the “Hearings Panel”).
On October 29, 2025, the Company received the determination of the Hearings Panel to deny the Company’s request for the continued